ConductScience.org, home

Paper39280671

Are primary tumors suitable for biomarker-guided treatment of metastatic urothelial cancer?

Scholtes MP and 4 others. Transl Androl Urol, 2024. Cited by 0 papers, by iCite.

Cite this record

ConductScience Library. Are primary tumors suitable for biomarker-guided treatment of metastatic urothelial cancer? Papers, record 39280671. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/39280671

Download JSON
Sources
11 sources
Release
papers-2026-11-12-0.1.0

Paper

PubMed's record of the paper, with iCite's citation figures. No abstract is shown.

Title
Are primary tumors suitable for biomarker-guided treatment of metastatic urothelial cancer?
PubMed
Journal
Transl Androl Urol
PubMed
Year
2024
PubMed
Publication types
Editorial, Comment
PubMed
Citations, by iCite
0
iCite
Relative citation ratio, by iCite
0.0, provisional
iCite
Revised in PubMed
2024-09-18
PubMed

Authors5

The authors in the order PubMed's record lists them, with the ORCID iDs it states.

OrderAuthorForenameKindORCID iD
1Scholtes MPMathijs Phttps://orcid.org/0000-0002-5205-097X
2van Leenders GJLHGeert J L Hhttps://orcid.org/0000-0003-2176-9102
3Robbrecht DGJDebbie G Jhttps://orcid.org/0000-0003-2490-9991
4Boormans JLJoost Lhttps://orcid.org/0000-0002-5127-0436
5Zuiverloon TCMTahlita C Mhttps://orcid.org/0000-0003-0991-0812

Source PubMed

Download CSV of authors

Topics0

NLM's MeSH indexing of the paper, its major topics first.

None in this release.

Comments and corrections1

PubMed's comments and corrections, NLM's own indexing: retractions first, then expressions of concern, errata and updates, and comments last.

KindPMIDTitleIn Papers
Comment on37031005Molecular Urothelial Tumor Cell Subtypes Remain Stable During Metastatic Evolution.https://conductscience.org/library/papers/37031005

Source PubMed

Download CSV of comments and corrections

References25

The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.

OrderPMIDTitleJournalYearIn PapersSource
137031005Molecular Urothelial Tumor Cell Subtypes Remain Stable During Metastatic Evolution.Eur Urol2024https://conductscience.org/library/papers/37031005PubMed
238196202Associations of TACSTD2/TROP2 and NECTIN-4/NECTIN-4 with molecular subtypes, PD-L1 expression, and FGFR3 mutational status in two advanced urothelial bladder cancer cohorts.Histopathology2024https://conductscience.org/library/papers/38196202PubMed
336372626Spatial Immunephenotypes of Distant Metastases but not Matched Primary Urothelial Carcinomas Predict Response to Immune Checkpoint Inhibition.Eur Urol2023https://conductscience.org/library/papers/36372626PubMed
430003574Concordance of PD-L1 expression in matched urothelial bladder cancer specimens.Histopathology2018https://conductscience.org/library/papers/30003574PubMed
531563503A Consensus Molecular Classification of Muscle-invasive Bladder Cancer.Eur Urol2020https://conductscience.org/library/papers/31563503PubMed
632031899EV-101: A Phase I Study of Single-Agent Enfortumab Vedotin in Patients With Nectin-4-Positive Solid Tumors, Including Metastatic Urothelial Carcinoma.J Clin Oncol2020https://conductscience.org/library/papers/32031899PubMed
736543146Genomic heterogeneity as a barrier to precision oncology in urothelial cancer.Cell Rep2022https://conductscience.org/library/papers/36543146PubMed
830007816Evolution of PD-1 and PD-L1 Gene and Protein Expression in Primary Tumors and Corresponding Liver Metastases of Metastatic Bladder Cancer.Eur Urol2018https://conductscience.org/library/papers/30007816PubMed
933929895TROPHY-U-01: A Phase II Open-Label Study of Sacituzumab Govitecan in Patients With Metastatic Urothelial Carcinoma Progressing After Platinum-Based Chemotherapy and Checkpoint Inhibitors.J Clin Oncol2021https://conductscience.org/library/papers/33929895PubMed
1037516671Letter to the editor for the article "Molecular urothelial tumor cell subtypes remain stable during metastatic evolution".World J Urol2023https://conductscience.org/library/papers/37516671PubMed
1137268487
Re: Alexander Cox, Niklas Klümper, Johannes Stein, et al. Molecular Urothelial Tumor Cell Subtypes Remain Stable During Metastatic Evolution. Eur Urol. In press. https://doi.org/10.1016/j.eururo.2023.03.020.
Eur Urol2023https://conductscience.org/library/papers/37268487PubMed
1234261585PD-L1 expression in bladder cancer: Which scoring algorithm in what tissue?Urol Oncol2021https://conductscience.org/library/papers/34261585PubMed
1335086719Comprehensive Molecular Characterization Reveals Genomic and Transcriptomic Subtypes of Metastatic Urothelial Carcinoma.Eur Urol2022https://conductscience.org/library/papers/35086719PubMed
1435216942TROP2 Expression Across Molecular Subtypes of Urothelial Carcinoma and Enfortumab Vedotin-resistant Cells.Eur Urol Oncol2022https://conductscience.org/library/papers/35216942PubMed
1527091807Tumor heterogeneity of fibroblast growth factor receptor 3 (FGFR3) mutations in invasive bladder cancer: implications for perioperative anti-FGFR3 treatment.Ann Oncol2016https://conductscience.org/library/papers/27091807PubMed
1638020299Immunohistochemical expression of TROP‑2 (TACSTD2) on the urothelial carcinoma of the urinary bladder and other types of cancer.Oncol Lett2023https://conductscience.org/library/papers/38020299PubMed
1734861372Bladder cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up.Ann Oncol2022https://conductscience.org/library/papers/34861372PubMed
1836534531Membranous NECTIN-4 Expression Frequently Decreases during Metastatic Spread of Urothelial Carcinoma and Is Associated with Enfortumab Vedotin Resistance.Clin Cancer Res2023https://conductscience.org/library/papers/36534531PubMed
1937870920Erdafitinib or Chemotherapy in Advanced or Metastatic Urothelial Carcinoma.N Engl J Med2023https://conductscience.org/library/papers/37870920PubMed
2027749842Clonal evolution of chemotherapy-resistant urothelial carcinoma.Nat Genet2016https://conductscience.org/library/papers/27749842PubMed

See all 25 referencesDownload CSV of references

Data dates

The date of each source this release read.

PubMed
2026-11-06
PubMed
iCite
2026-11-05
iCite
PMC's ID file
2026-11-05
PMC's ID file
NIH RePORTER's grant and paper links
2026-11-01
NIH RePORTER's grant and paper links
Trials
2026-11-12
Gene search
2026-11-11
Pipelines
2026-09-18

None in this release

  • Grants
  • Trials
  • Cited by
  • Genes
  • Drugs
  • Data

Sources 11

  • ChEMBL, through Open TargetsCC BY-SA 3.0
  • ClinicalTrials.govNo license stated
  • HGNCCC0
  • iCiteCC BY 4.0
  • NCBI GenePublic domain (US government)
  • NIH RePORTER's grant and paper linksPublic domain
  • Open TargetsCC0 1.0
  • PMC's ID filePublic domain (US government)
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0
Each source's terms
  • ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • ClinicalTrials.govnone stated
  • HGNCCC0: https://www.genenames.org/about/license/
  • iCiteCC BY 4.0
  • NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
  • Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this paper from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/papers/v1/39280671

GET https://conductscience.org/api/papers/v1/39280671/references?page=2